JP5802737B2 - 新規な多形体 - Google Patents

新規な多形体 Download PDF

Info

Publication number
JP5802737B2
JP5802737B2 JP2013501934A JP2013501934A JP5802737B2 JP 5802737 B2 JP5802737 B2 JP 5802737B2 JP 2013501934 A JP2013501934 A JP 2013501934A JP 2013501934 A JP2013501934 A JP 2013501934A JP 5802737 B2 JP5802737 B2 JP 5802737B2
Authority
JP
Japan
Prior art keywords
solid form
proline
benzylcarbamoyl
tetrahydro
dimethylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013501934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523706A (ja
JP2013523706A5 (enExample
Inventor
ユーアン ヘンリク シェルストレーム
ユーアン ヘンリク シェルストレーム
ビョルン エリク ヨハンソン
ビョルン エリク ヨハンソン
トマス ヴィルヘルムセン
トマス ヴィルヘルムセン
Original Assignee
ヴァンティア リミテッド
ヴァンティア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァンティア リミテッド, ヴァンティア リミテッド filed Critical ヴァンティア リミテッド
Publication of JP2013523706A publication Critical patent/JP2013523706A/ja
Publication of JP2013523706A5 publication Critical patent/JP2013523706A5/ja
Application granted granted Critical
Publication of JP5802737B2 publication Critical patent/JP5802737B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
JP2013501934A 2010-04-01 2011-03-31 新規な多形体 Expired - Fee Related JP5802737B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1005623.2 2010-04-01
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
US34704810P 2010-05-21 2010-05-21
US61/347,048 2010-05-21
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (3)

Publication Number Publication Date
JP2013523706A JP2013523706A (ja) 2013-06-17
JP2013523706A5 JP2013523706A5 (enExample) 2015-05-14
JP5802737B2 true JP5802737B2 (ja) 2015-11-04

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501934A Expired - Fee Related JP5802737B2 (ja) 2010-04-01 2011-03-31 新規な多形体

Country Status (20)

Country Link
US (1) US9079881B2 (enExample)
EP (1) EP2552910B1 (enExample)
JP (1) JP5802737B2 (enExample)
KR (1) KR101792621B1 (enExample)
CN (1) CN102918038B (enExample)
CA (1) CA2795109C (enExample)
DK (1) DK2552910T3 (enExample)
ES (1) ES2538085T3 (enExample)
GB (1) GB201005623D0 (enExample)
HR (1) HRP20150513T1 (enExample)
HU (1) HUE026442T2 (enExample)
ME (1) ME02102B (enExample)
MX (1) MX2012011382A (enExample)
PL (1) PL2552910T3 (enExample)
PT (1) PT2552910E (enExample)
RS (1) RS53956B1 (enExample)
RU (1) RU2559633C2 (enExample)
SI (1) SI2552910T1 (enExample)
SM (1) SMT201500107B (enExample)
WO (1) WO2011121308A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) 2011-03-31 2011-05-18 Vantia Ltd New process
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
CN108026059A (zh) * 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
DK1000062T3 (da) 1997-07-30 2004-11-22 Wyeth Corp Tricykliske vasopressinagonister
DE69826677T2 (de) 1997-07-30 2005-02-10 Wyeth Trizyclische Vasopressin-Agonisten
DK1149096T3 (da) 1999-02-04 2003-04-07 Wyeth Corp Tricykliske pyridin-N-oxider som vasopressinagonister
JP2002536377A (ja) 1999-02-04 2002-10-29 ワイス バソプレシンアゴニストとしてのチエエニルベンゾイルベンズアゼピン類
WO2000046225A2 (en) 1999-02-04 2000-08-10 American Home Products Corporation Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
CN1339037A (zh) 1999-02-04 2002-03-06 美国家用产品公司 吡咯并苯并二吖庚因酰胺血管加压素激动剂
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents

Also Published As

Publication number Publication date
CN102918038A (zh) 2013-02-06
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
KR20130023218A (ko) 2013-03-07
US20140296213A1 (en) 2014-10-02
CN102918038B (zh) 2015-09-09
PT2552910E (pt) 2015-05-13
HUE026442T2 (en) 2016-06-28
RS53956B1 (sr) 2015-08-31
CA2795109C (en) 2018-04-17
PL2552910T3 (pl) 2015-07-31
EP2552910A1 (en) 2013-02-06
CA2795109A1 (en) 2011-10-06
KR101792621B1 (ko) 2017-11-02
EP2552910B1 (en) 2015-03-11
JP2013523706A (ja) 2013-06-17
DK2552910T3 (en) 2015-04-07
HRP20150513T1 (hr) 2015-06-05
ES2538085T3 (es) 2015-06-17
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
GB201005623D0 (en) 2010-05-19
MX2012011382A (es) 2013-01-29
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
ME02102B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
JP5802737B2 (ja) 新規な多形体
AU2012331395B2 (en) Ivabradine hydrochloride form IV
KR20220008273A (ko) 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
TW200825077A (en) Crystal forms of 9-hydroxy-risperidone (paliperidone)
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2019062854A1 (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
KR20240167881A (ko) 5-meo-dmt의 결정질 브롬화수소염
WO2018103726A1 (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
WO2019183916A1 (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
CN102459237A (zh) 6-(1h-咪唑-1-基)-2-苯基喹唑啉的晶型
WO2015003571A1 (zh) 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2019210511A1 (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
JP5889391B2 (ja) １−（２−メチル−４−（２，３，４，５−テトラヒドロ−１−ベンズアゼピン−１−イルカルボニル）ベンジルカルバモイル）−ｌ−プロリン−ｎ，ｎ−ジメチルアミドの調製方法
US7777049B2 (en) Crystalline forms of Rizatriptan benzoate
US20200283381A1 (en) Solid state forms of elafibranor
TW201600518A (zh) 阿利沙坦酯結晶及其製備方法及含有該結晶的藥物組合物
US20110165202A1 (en) Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
WO2015161730A1 (zh) 一种氯卡色林共晶及其制备方法、药物组合物和用途
WO2025035486A1 (zh) 一种酪氨酸激酶抑制剂的可药用盐、结晶形式及其制备方法
CN118974018A (zh) 达罗他胺的晶型
WO2023123742A1 (zh) PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150317

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150831

R150 Certificate of patent or registration of utility model

Ref document number: 5802737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees